Cover Image
Read Now

Clinical review report: Insulin degludec and liraglutide injection (Xultophy) (Novo nordisk Canada Inc.)

The objective of this review is to perform a systematic review of the beneficial and harmful effects of IDegLira as an adjunct to lifestyle modifications, for the treatment of adults with Type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH December 2019, 2019
Edition:Version: final (with redactions)
Series:CADTH common drug review
Subjects:
Drug Combinations
Blood Glucose / Drug Effects
Hypoglycemic Agents / Therapeutic Use
Diabetes Mellitus, Type 2 / Drug Therapy
Liraglutide / Therapeutic Use
Treatment Outcome
Insulin, Long-acting / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of this review is to perform a systematic review of the beneficial and harmful effects of IDegLira as an adjunct to lifestyle modifications, for the treatment of adults with Type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 U daily) or liraglutide (less than or equal to 1.8 mg daily) do not provide adequate glycemic control
Physical Description:1 PDF file (194 pages) illustrations

Similar Items